 Humanigen Inc NASDAQ: HGEN is prepping its COVID-19 drug lenzilumab for an emergency use authorization with the FDA before the months end. According to its Q1 financial report out Thursday after-hours, the company said it had recently held a meeting with FDA to discuss the filing of a EUA for lenzilumab, specifically for hospitalized, hypoxic COVID-19 patients, at the end of May. 